Author: hivecanada
Protected: Watch the third and final video in the series “All Things Urticaria: A Fire Side Chat with Prof. Marcus Maurer” (Part 3 of 3, Video 11 min)
Protected: Watch the second video in the series “All Things Urticaria: A Fire Side Chat with Prof. Marcus Maurer” (Part 2 of 3, Video 4 min)
Protected: Video now available: “All Things Urticaria: A Fire Side Chat with Prof. Marcus Maurer” (Part 1 of 3, Video 15 min)
The Buzz, Issue #15 is now out! This month, we highlight a survey of Canadian practice patterns in atopic dermatitis, a Canadian position statement on preventing food allergy in high-risk infants, and the World Allergy Organization’s guidelines on immunotherapy for cow’s milk allergy. We also feature a Canadian survey of attitudes towards COVID-19 vaccination among patients with primary immunodeficiency and look into the sensitivity and specificity of using TPO and IgE as diagnostic biomarkers for autoimmune CSU.
The Buzz Issue #15, July 2022 edition, will be sent to all HIVE members by email on Mon, June 27th, and can be accessed online here.
To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
Protected: Whiteboard Video #1: Dr. Sari Herman presents the first of a three-part animated video series on diagnosis and treatment for patients with chronic urticaria (EN & FR, video 2 min)
The Buzz, Issue #14 is now out! In this month’s issue, we highlight a possible new predictive biomarker for severe anaphylaxis in children, the use of direct oral challenge to de-label penicillin allergy during pregnancy, and three publications in atopic dermatitis: new data with the JAK1-selective inhibitor abrocitinib, a structured appraisal of the clinical practice guidelines, and a metaanalysis of the literature on the use of dilute bleach baths.
The Buzz Issue #14, June 2022 edition, will be sent to all HIVE members by email on Mon, May 30th, and can be accessed online here.
To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The HIVE Refresh!
Dear HIVE members,
We looked for your feedback, reflected upon it and refreshed our purpose and process to go beyond Chronic Spontaneous Urticaria (CSU) to include keywords of common interest to allergists, immunologists and dermatologists.
You will see this reflected in your weekly HIVE email digest, in the “New Articles From Your Sources” section as well as in the “New publications by members” section. All other member publications not captured within the new keyword parameters are now featured in the “HIVE Plus community” section of the email digests.
We hope that this configuration/curation better suits your needs and acknowledges your broader contributions in this field. If you have any comments, questions or concerns, please let us know by replying to your email digest or emailing us at hive@sosido.com.
Thank you.
The Buzz, Issue #13 is now out! This month’s publications look at peanut cross-contamination rates, the safety of second SARS-CoV-2 vaccine doses following an immediate allergic reaction to dose 1, the risk of thyroid autoimmunity in the setting of chronic urticaria, a review of cannabis-related allergy, and another scoping review about culprit drug identification.
The Buzz Issue #13, May 2022 edition, will be sent to all HIVE members by email on Mon, May 2nd, and can be accessed online here.
To view all issues of The Buzz, go to thehivecommunity.org/the-buzz
The HIVE Community 